PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
EBIT growth similar to AGEN's 100.00%. Walter Schloss might infer both firms share similar operational efficiencies.
-121.69%
Negative operating income growth while AGEN is at 48.60%. Joel Greenblatt would press for urgent turnaround measures.
-139.60%
Negative net income growth while AGEN stands at 44.79%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-131.82%
Negative EPS growth while AGEN is at 51.87%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-131.82%
Negative diluted EPS growth while AGEN is at 51.87%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.70%
Negative OCF growth while AGEN is at 10.59%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-31.70%
Negative FCF growth while AGEN is at 10.82%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
95.37%
Positive long-term OCF/share growth while AGEN is negative. John Neff would see a structural advantage in sustained cash generation.
75.95%
5Y OCF/share CAGR is similar to AGEN's 77.99%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
7.00%
3Y OCF/share CAGR under 50% of AGEN's 74.19%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
81.58%
Similar net income/share CAGR to AGEN's 81.60%. Walter Schloss would see parallel tailwinds or expansions for both firms.
47.75%
5Y net income/share CAGR at 50-75% of AGEN's 83.20%. Martin Whitman might see a shortfall in operational efficiency or brand power.
-122.09%
Negative 3Y CAGR while AGEN is 78.94%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-94.45%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
58.16%
5Y equity/share CAGR at 50-75% of AGEN's 90.61%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
-73.50%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.73%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-21.56%
We have a declining book value while AGEN shows 81.36%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-8.90%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
60.05%
R&D growth of 60.05% while AGEN is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
231.77%
We expand SG&A while AGEN cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.